Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

(2020) Chaolin Huang et al.   LANCET

COVID-19: combining antiviral and anti-inflammatory treatments

(2020) Justin Stebbing et al.   LANCET INFECTIOUS DISEASES

A Novel Coronavirus from Patients with Pneumonia in China, 2019

(2020) Na Zhu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

(2020) Xiaobo Yang et al.   Lancet Respiratory Medicine

Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission

(2020) Jennifer Lighter et al.   CLINICAL INFECTIOUS DISEASES

Clinical and immunological features of severe and moderate coronavirus disease 2019

(2020) Guang Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Clinical and demographic characteristics of patients dying from COVID-19 in Italy versus China

(2020) Giuseppe Lippi et al.   JOURNAL OF MEDICAL VIROLOGY

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

(2020) F. La Rosée et al.   LEUKEMIA

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey

(2015) R Zeiser et al.   LEUKEMIA